US2009104213A1PendingUtilityA1

Vaccine for House Dust Mite Allergen Using Naked DNA

62
Assignee: YOO TAI JUNEPriority: Feb 25, 1999Filed: Sep 4, 2008Published: Apr 23, 2009
Est. expiryFeb 25, 2019(expired)· nominal 20-yr term from priority
Inventors:Tai June Yoo
A61K 2039/53A61K 31/711C07K 14/4713A61K 39/35A61P 11/06A61K 48/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Vaccination with the DNA encoding T-cell epitopes to the house dust mite Dermatophagoides pteronyssimus (Der p) and Dermatophagoides farinae (Der f were effective in the inhibition of the allergen induced IgE synthesis. Gene therapy using T-cell epitope encoding DNA is useful in combating allergic disease.

Claims

exact text as granted — not AI-modified
1 . A composition comprising a mixture of naked DNA comprising nucleic acid sequences encoding portions of dust mite antigens amplified by two or more primer pairs selected from the group consisting of SEQ ID NO:45 and SEQ ID NO:46 for Der p 1, SEQ ID NO:47 and SEQ ID NO:48 for Der p 1, SEQ ID NO:49 and SEQ ID NO:50 for Der p 2, SEQ ID NO: 51 and SEQ ID NO:52 for Der p 2, SEQ ID NO: 53 and SEQ ID NO:54 for Der p 2, SEQ ID NO:1 and SEQ ID NO:2 for Der p 1, SEQ ID NO:3 and SEQ ID NO:4 for Der p 1, SEQ ID NO:5 and SEQ ID NO:6 for Der p 1, SEQ ID NO:7 and SEQ ID NO:8 for Der p 2, SEQ ID NO:9 and SEQ ID NO:10 for Der p 2, SEQ ID NO:21 and SEQ ID NO:22 for Der p 1, SEQ ID NO:23 and SEQ ID NO:24 for Der p 2, SEQ ID NO:25 and SEQ ID NO:26 for Der p 3, SEQ ID NO:27 and SEQ ID NO:28 for Der f 1, SEQ ID NO:29 and SEQ ID NO:30 for Der f 2, and SEQ ID NO:31 and SEQ ID NO:32 for Der f 3. 
     
     
         2 . The composition of  claim 1 , wherein each of said sequences is on separate naked DNA. 
     
     
         3 . The composition of  claim 1 , wherein said composition is administered to a mammal. 
     
     
         4 . The composition of  claim 1 , wherein said composition is administered to a human. 
     
     
         5 . A method comprising administering to a human, a composition comprising a pharmaceutically acceptable carrier and a mixture of naked DNA comprising sequences encoding portions of immunogenic dust mite antigens amplified by two or more primer pairs selected from the group consisting of SEQ ID NO:45 and SEQ ID NO:46 for Der p 1, SEQ ID NO:47 and SEQ ID NO:48 for Der p 1, SEQ ID NO:49 and SEQ ID NO:50 for Der p 2, SEQ ID NO: 51 and SEQ ID NO:52 for Der p 2, SEQ ID NO: 53 and SEQ ID NO:54 for Der p 2, SEQ ID NO:1 and SEQ ID NO:2 for Der p 1, SEQ ID NO:3 and SEQ ID NO:4 for Der p 1, SEQ ID NO:5 and SEQ ID NO:6 for Der p 1, SEQ ID NO:7 and SEQ ID NO:8 for Der p 2, SEQ ID NO:9 and SEQ ID NO:10 for Der p 2, SEQ ID NO:21 and SEQ ID NO:22 for Der p 1, SEQ ID NO:23 and SEQ ID NO:24 for Der p 2, SEQ ID NO:25 and SEQ ID NO:26 for Der p 3, SEQ ID NO:27 and SEQ ID NO:28 for Der f 1, SEQ ID NO:29 and SEQ ID NO:30 for Der f 2, and SEQ ID NO:31 and SEQ ID NO:32 for Der f 3. 
     
     
         6 . The composition of  claim 1 , wherein the DNA is plasmid DNA. 
     
     
         7 . The composition of  claim 1 , wherein at least one portion of an immunogenic dust mite antigen is from Der p 1 and another portion of an immunogenic dust mite antigen is from Der p 2. 
     
     
         8 . The composition of  claim 1 , wherein the naked DNA is a plasmid comprising a promoter/enhancer transcriptionally linked to said portions of dust mite antigens. 
     
     
         9 . The method of  claim 5 , wherein the DNA is plasmid DNA. 
     
     
         10 . The method of  claim 5 , wherein said administering comprises one or more methods selected from the group consisting essentially of intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection. 
     
     
         11 . The method of  claim 5 , wherein each of said sequences is on separate naked DNA. 
     
     
         12 . The method of  claim 5 , wherein the composition is administered to a human having an allergic reaction to dust mites. 
     
     
         13 . The method of  claim 5 , wherein administering suppresses IgE antibody production in said human. 
     
     
         14 . The method of  claim 5 , wherein administering increases interferon-γ expression in said human. 
     
     
         15 . The method of  claim 5 , wherein administering induces Th1 immune response in said human. 
     
     
         16 . The method of  claim 5 , wherein the naked DNA is a plasmid comprising a promoter/enhancer transcriptionally linked to said portions of dust mite antigens. 
     
     
         17 . The method of  claim 5 , wherein said method comprises administering said naked DNA with a transfection facilitating material. 
     
     
         18 . The method of  claim 5 , wherein the composition comprises at least one portion of an immunogenic dust mite antigen is from Der p 1 and another portion of an immunogenic dust mite antigen is from Der p 2. 
     
     
         19 . The method of  claim 5 , wherein said portions of immunogenic dust mite antigens are portions of Der p 1 amplified by two or more primer pairs selected from the group consisting of SEQ ID NO:45 and SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48, SEQ ID NO:1 and SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, and SEQ ID NO:21 and SEQ ID NO:22. 
     
     
         20 . The method of  claim 5 , wherein said portions of immunogenic dust mite antigens are portions of Der p 2 amplified by two or more primer pairs selected from the group consisting of SEQ ID NO:49 and SEQ ID NO:50, SEQ ID NO: 51 and SEQ ID NO:52, SEQ ID NO: 53 and SEQ ID NO:54, SEQ ID NO:7 and SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, and SEQ ID NO:23 and SEQ ID NO:24.

Join the waitlist — get patent alerts

Track US2009104213A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.